Abstract

A MIL series metal‒organic framework (MOF), MIL-100(Fe), was successfully synthesized at the nanoscale and fully characterized by TEM, TGA, XRD, FTIR, DLS, and BET. A toxicological assessment was performed using two different cell lines: human normal liver cells (HL-7702) and hepatocellular carcinoma (HepG2). In vitro cytotoxicity of MIL-100(Fe) was evaluated by the MTT assay, LDH releasing rate assay, DAPI staining, and annexin V/PI double staining assay. The safe dose of MIL-100(Fe) was 80 μg/mL. It exhibited good biocompatibility, low cytotoxicity, and high cell survival rate (HL-7702 cells’ viability >85.97%, HepG2 cells’ viability >91.20%). Therefore, MIL-100(Fe) has a potential application as a drug carrier.

Highlights

  • Metal-organic frameworks (MOFs) are the latest class of crystalline hybrid materials developed over the last 20 years [1]

  • The invitro vitrotoxicity toxicity test fast,effective, effective, and According to previous studies, MIL-100(Fe) wasThe synthesized by thetest hydro-thermal method

  • Results the MIL-100(Fe) simulated pattern, the diffraction peaks of the experimental group match well, which indicates that the synthesis of MIL-100(Fe) crystal is successful

Read more

Summary

Introduction

Metal-organic frameworks (MOFs) are the latest class of crystalline hybrid materials developed over the last 20 years [1]. The high versatility of MOFs is shown by their various applications over the past 10 years, including catalysis [6], sensing [7], gas storage [8], bio-imaging [9], and magnetism [10]. Because of their large specific surface area, connectivity polyhedron, high pore volume, high stability, non-toxicity, biocompatibility, and small size, MOFs have become the most promising nanocarriers in the biomedical field [11,12,13,14]. MOFs can be used in a variety of designs, such as imaging agents for early and minimally invasive diagnostics [15], specific cell and tissue (more commonly tumor tissue) targeting [16], high drug loading [17], increased local drug concentration [18], and developing drug delivery preparations [19]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call